OR WAIT 15 SECS
© 2021 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Michelle Maskaly is Pharmaceutical Executive's Senior Editor. Follow her on Twitter @mmaskaly or email her at michelle.maskaly@ubm.com
Pharmaceutical Executive
Enzychem Lifesciences explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.
Enzychem Lifesciences’ Chairman and CEO, Ki-Young Sohn explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.
He spoke to Pharm Exec during a company event in New York City.